Riken Vitamin Co., Ltd. revised consolidated earnings guidance for the fiscal year ending March 31, 2024. For the year, the company expects net sales to be JPY 90,600 million against previous guidance of JPY 92,000 million. Operating income to be JPY 7,700 million against previous guidance of JPY 6,800 million. Profit
attributable to owners of parent to be JPY 6,600 million against previous guidance of JPY 5,600 million. Earnings per share to be JPY 201.09 against previous guidance of JPY 170.64.